Vaccines Market Size, Share, Growth and Forecast, 2025-2035

Adult programs and new platforms lift immunization spending

The global vaccines market was valued at USD 75.45 billion in 2025 and is projected to increase from USD 80.88 billion in 2026 to USD 151.20 billion by 2035, registering a CAGR of 7.20% during 2026–2035. Demand rises because national programs keep expanding childhood schedules, while health systems add pneumococcal, RSV, shingles and influenza shots for older adults. North America held the largest regional share, 40.0% in 2025, because the United States pays high prices for adult and newer pediatric products. Asia Pacific is the fastest-growing region at 8.28% a year, as India and China scale domestic manufacturing and add new antigens to public schedules. The commercial picture also changed in May 2024, when the first mRNA product for a disease other than COVID-19 won U.S. approval. As a result, mRNA, conjugate and combination products are taking a larger share of new spending.

Which immunization products and buyers does this analysis count?

Human prophylactic immunization products for viral and bacterial diseases, covering subunit, inactivated, live attenuated, mRNA and viral vector technologies in monovalent and multivalent forms, form the value counted here. Governments, international procurement agencies, hospitals and retail pharmacies buy these products for children and adults.

Veterinary products, therapeutic cancer immunotherapies and monoclonal antibodies given for passive protection sit outside the value counted here. The value chain runs from antigen development and fill-finish manufacturing through cold chain distribution to administration by clinics, pharmacies and public health programs.

Subunit products lead while mRNA grows fastest

Which technologies account for most immunization spending?

Based on technology, the market is categorized into subunit, inactivated, live attenuated, mRNA and viral vector products. The Subunit Vaccines group led with 42.0% of 2025 value, because conjugate, recombinant protein and toxoid products dominate pneumococcal, shingles, HPV and meningococcal programs. mRNA Vaccines grow fastest at 9.04% a year, as approvals extend beyond COVID-19 into RSV and other respiratory targets. Inactivated products remain central to polio, hepatitis A and influenza programs worldwide.

How do buyers procure immunization products?

Based on distribution channel, the market is categorized into hospital pharmacies, retail pharmacies and government suppliers. Government Suppliers led with 48.0% of 2025 value, because national programs, UNICEF and Gavi buy most childhood doses through tenders. Retail Pharmacies grow fastest at 8.37% a year, as pharmacists give more adult influenza, COVID-19, RSV and shingles shots. Hospital pharmacies serve birth doses, travelers and high-risk patients in specialist care.

Do adults or children account for more spending?

Based on age group, the market is categorized into adult and children. Adult led with 55.0% of 2025 value, because high-priced pneumococcal, RSV, shingles and COVID-19 products target older adults. The same group grows fastest at 7.77% a year, as more countries add adult schedules. Childhood programs still deliver most doses, though public tender prices keep their value per dose low.

Coverage gaps, Gavi funding and adult products drive demand

How do childhood coverage gaps sustain program demand?

Each new birth cohort needs a full primary series, and millions of infants still miss basic doses every year in poorer countries. According to WHO and UNICEF estimates, 85% of infants, about 109 million children, completed three DTP doses in 2024. The same estimates counted 14.3 million zero-dose children who received no vaccine at all. UNICEF delivered about 2.787 billion doses to 99 countries in 2024, enough to reach roughly 45% of children under five. As a result, government suppliers held 48.0% of 2025 value, the largest channel share, and tender volumes stay high even as prices per dose remain low.

Why does Gavi funding shape demand in poorer countries?

Many low-income countries depend on donor money to introduce newer antigens, and Gavi co-finances programs in 57 of them. On June 25, 2025, Gavi raised more than USD 9 billion at its Brussels summit for the 2026 to 2030 period. Gavi aims to protect 500 million children over that period and avert 8 million to 9 million future deaths. At least 17 African countries had introduced a malaria vaccine by the end of 2024, after Cameroon started in January 2024. In turn, the Middle East and Africa grows at 8.08% a year, and medical refrigerators remain essential for the cold chain.

Download Free Sample

How are adult products raising spending per person?

Older adults now receive several high-priced shots across their later years, which lifts value per person well above childhood levels. On June 17, 2024, the FDA approved Merck's Capvaxive for adults 18 and older against invasive pneumococcal disease and pneumonia. Merck said the 21-valent product covers about 84% of invasive cases in adults 50 and older, compared with about 52% for PCV20. On Oct. 22, 2024, Pfizer announced FDA approval of Abrysvo for adults 18 to 59 at increased RSV risk, widening use beyond older adults. As a result, adults led age groups with 55.0% of 2025 value, and adult demand keeps growing.

Why is mRNA technology moving beyond COVID-19?

The mRNA format allows fast design changes, so developers now aim it at RSV, influenza and other respiratory viruses with regulatory support. On May 31, 2024, the FDA approved Moderna's mRESVIA for adults 60 and older, the first mRNA product cleared for a disease other than COVID-19. On May 31, 2025, Moderna announced approval of mNEXSPIKE, which used a 10 microgram dose, one-fifth of the comparator dose in its trial. BioNTech closed its CureVac exchange offer on Dec. 18, 2025, with about 86.75% of shares tendered. In turn, mRNA products grow fastest at 9.04% a year, linked to wider mRNA therapeutics research.

Higher valency, pipeline deals and home flu spray openings

How is the rise of higher-valency products changing schedules?

Makers are packing more strains into each shot, because fewer injections ease scheduling for clinics, schools and families. On Feb. 14, 2025, the FDA approved GSK's Penmenvy for people aged 10 to 25 against meningococcal serogroups A, B, C, W and Y. The phase 3 study enrolled 3,650 participants and met all 11 primary endpoints, according to trade reports. Penmenvy became the second pentavalent meningococcal product in the United States, after Pfizer's Penbraya. Merck's 21-valent Capvaxive also covers eight serotypes not found in older adult products. As a result, multivalent products gain share in adolescent and adult schedules, and older single-strain products lose ground.

Are pipeline acquisitions reshaping the competitive field?

Large companies are buying smaller developers, because respiratory combinations and new platforms need specialist design tools and experienced research teams. On Dec. 4, 2025, Sanofi completed its acquisition of Vicebio, adding an early RSV and human metapneumovirus combination candidate. Vicebio also brought its Molecular Clamp technology, which Sanofi described as a non-mRNA design option. BioNTech completed its CureVac exchange offer two weeks later, on Dec. 18, 2025. However, Johnson & Johnson stopped its phase 3 E. coli vaccine trial in February 2025 after an interim analysis showed weak efficacy. In turn, buyers favor platforms with proven clinical data and manufacturing depth.

Download Free Sample

Can home flu spray delivery open a retail channel?

Self-administration removes the clinic visit for healthy children and adults, which creates a new path to patients who skip annual shots. On Sept. 20, 2024, the FDA approved AstraZeneca's FluMist for self-administration by adults up to age 49 and caregiver use for ages 2 to 17. Orders go through FluMist Home, an online pharmacy where a pharmacist reviews an eligibility questionnaire before shipping. FluMist became the only self-administered influenza product approved in the United States. As a result, retail pharmacies grow fastest at 8.37% a year, alongside seasonal influenza prevention and other home-delivered pharmacy services.

Where can HPV and measles catch-up campaigns add demand?

Coverage for several antigens remains far below global targets, which leaves room for large catch-up drives in many countries. In 2024, only 31% of eligible adolescent girls worldwide received at least one HPV dose, up from 17% in 2019. Measles first-dose coverage stood at 84% and second-dose coverage at 76%, below the levels needed to stop outbreaks. The number of countries with large or disruptive measles outbreaks rose to 60 in 2024, from 33 in 2022. In turn, Asia Pacific programs gain volume as India and other large countries expand HPV and measles campaigns in schools, clinics and community outreach sessions.

Aid cuts, misinformation and trial setbacks weigh on demand

How do aid cuts threaten program funding?

Many low-income countries rely on donors to buy newer antigens, so smaller aid budgets slow introductions. Gavi raised more than USD 9 billion in June 2025, below its USD 11.9 billion target for 2026 to 2030. The WHO Director-General warned that drastic aid cuts threaten decades of progress. As a result, some countries may delay introductions of malaria, HPV and pneumococcal products in the next few years, which lowers expected tender volumes for suppliers.

Why does misinformation reduce uptake?

Doubts about safety lead some parents and adults to delay or refuse shots, which lowers coverage. WHO and UNICEF named misinformation as a threat to coverage in their July 2025 release. Measles outbreaks have spread to more countries as coverage stalls below target levels. As a result, health systems must spend more on outreach and communication, which slows growth in adult programs in high-income markets and raises program costs.

How do trial failures raise development risk?

Late-stage programs consume years of spending before results arrive, so a failed study is costly for developers and partners. Johnson & Johnson stopped its phase 3 E. coli trial in February 2025 after interim data showed insufficient efficacy. Sanofi had licensed the candidate to the company in October 2023 for USD 250 million upfront. As a result, investors and partners now demand stronger early data before funding large trials, which slows the path from discovery to licensed products.

Why do conflict and fragile states limit reach?

Clinics, cold chains and trained staff are hard to maintain during crises, which leaves many children unreached for years. WHO and UNICEF reported that 26 countries affected by fragility or conflict hold half of all unvaccinated children. Supply in these areas depends on contract manufacturing capacity and donor logistics. As a result, many zero-dose children remain out of reach, and suppliers see uneven demand from these countries.

North America leads value as Asia Pacific grows fastest

Why does North America hold the largest regional share?

North America held a 40.0% share of 2025 value and grows at 6.68% a year through 2035. U.S. buyers pay high prices for pneumococcal, RSV, shingles, meningococcal and COVID-19 products. Recent approvals such as Capvaxive, Abrysvo for younger at-risk adults, Penmenvy and mNEXSPIKE add new products to adult and adolescent schedules. Retail pharmacies give a large share of adult shots, which widens access across the country.

What keeps Europe the second-largest region?

Europe held a 25.0% share of 2025 value and grows at 6.58% a year through 2035. National tenders in Germany, France, the United Kingdom, Italy and Spain buy pediatric, influenza and adult pneumococcal products at negotiated prices. Public programs also buy influenza and pediatric combination products in large annual volumes. However, tender pricing keeps value per dose below U.S. levels across most product classes.

Download Free Sample

How fast is Asia Pacific expanding immunization?

Asia Pacific held a 24.0% share of 2025 value and is the fastest-growing region at 8.28% a year. Serum Institute of India supplies large volumes for domestic and UNICEF programs, while Sinovac and Chongqing Zhifei serve China's public schedule. Rising incomes support private adult immunization in China, Japan, South Korea and Australia. As a result, both public and private demand rise faster than in other regions.

Where is Latin America adding demand?

Latin America held a 6.0% share of 2025 value and grows at 7.78% a year through 2035. Brazil, Mexico and Argentina buy most doses through public programs and regional pooled procurement.

What limits growth in the Middle East and Africa?

The Middle East and Africa held a 5.0% share of 2025 value and grows at 8.08% a year through 2035. Malaria product rollouts and Gavi support add volume, though prices per dose stay low.

Download Free Sample

Approvals, funding pledges and acquisitions since 2024

Platforms and formats reshaping immunization products

• mRNA platforms let developers change antigens quickly, which supports annual strain updates and new respiratory targets.
• Conjugate technology links sugars to carrier proteins, which raises protection against pneumococcal and meningococcal disease.
• Molecular Clamp design holds viral proteins in their prefusion shape, which supports non-mRNA RSV and metapneumovirus candidates.
• Needle-free nasal sprays allow home self-administration, which opens online pharmacy delivery for influenza protection.
• Combination formulations merge several antigens in one shot, which cuts clinic visits for adolescents and families.

Global originators and volume makers compete for tenders

Competition in the market splits between global originators of high-priced adult and pediatric products and volume makers that supply public tenders. Merck & Co., Inc., Pfizer Inc., GSK plc and Sanofi lead in pneumococcal, RSV, meningococcal, shingles and pediatric combination products. AstraZeneca competes in influenza with its nasal spray, while BioNTech SE and Moderna compete in mRNA. The Serum Institute of India supplies large volumes of low-cost doses to UNICEF and national programs. Sinovac Biotech Ltd. and Chongqing Zhifei Biological Products Co., Ltd. serve China's large public market. Johnson & Johnson narrowed its pipeline after a failed bacterial trial in 2025. However, originators keep the advantage in adult programs, where clinical data and serotype coverage decide recommendations.

Companies profiled and their roles in this market

Adult immunization and new platforms carry growth to 2035

Credence Research's view is that adult immunization and new platforms, rather than childhood volume, will carry most growth through 2035. The market grows at 7.20% a year as pneumococcal, RSV and mRNA products reach older adults in high-income countries. Childhood programs remain the backbone of dose volume, but tender pricing keeps their value growth modest. The strongest openings sit in mRNA, retail administration and Asia Pacific programs, while donor funding gaps and misinformation remain the main risks for buyers and suppliers.

How Credence Research built the immunization model

The report uses 2025 as the base year and 2026 to 2035 as the forecast period. Market values come from the Credence Research model, which builds spending by technology, distribution channel and age group. Regional and segment splits are Credence Research estimates informed by WHO and UNICEF coverage estimates, Gavi announcements, FDA approvals, regulatory filings and company releases. No primary interviews or surveys were used in preparing this edition of the report.

Pediatric, adult and mRNA immunization outlook to 2035

By 2035, the vaccines market is projected to reach USD 151.20 billion, with growth led by adult products, mRNA platforms and Asia Pacific. Subunit and conjugate products will remain the largest technology group as pneumococcal and meningococcal schedules widen. Donor funding will decide how quickly malaria, HPV and pneumococcal products reach low-income countries. Retail pharmacies and home delivery will handle a larger share of adult influenza, COVID-19 and RSV shots in high-income markets by the end of the forecast.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.